



Test Requisition for Tissue Culturing (Oncology)

COMPLETE ENTIRE FORM TO AVOID DELAYS

Baylor Genetics

2450 Holcombe Blvd, Houston, TX 77021-2024 | CLIA# 45D0660090

PATIENT INFORMATION						
Legal Name (Last, First, MI)		Date of Birth (MM/DD,	/yy) Sex Assign at Birth □ F □ M		nder (optional) Man □ Woman Self-described	□ Nonbinary
Genetic Ancestry: Ashkenazi Jewish Asian Black/African American French Canadian/Cajun Hispanic/Latino Mediterranean MRN Middle Eastern Native American Pacific Islander Portuguese White Unknown Other:						
Address City				State	_	Zip
Mobile # Email				Preferred Insura	d Billing ance □ Self-pay	☐ Institutional
SPECIMEN TRANSPORT Room Temperature						
Collection Date (MM/DD/YY): Time: AM PM Number of Specimens Submitted: Collection date is required for testing to proceed. Failure to provide may result in delays and/or test cancellation.						
Specimen Details: Tissue Type (e.g. skin): Site (e.g. left arm						
Testing laboratory handling instructions: Sample will be cultured at Baylor Genetics; 2 (two) T-25 flasks will			ole will not be frozer	n for long-te	rm storage.	
	Special Instructions					
ORDERING PHYSICIAN OR OTHER LICENSED MEDICAL PROFESSIONA	<u> </u>	ype: Physician/P	hysician Group	Refer		
Name (Last, First, Degree) Facilit	ity Name			INPI	+	
Kit Shipment Street Address City				Stat	e Zip	1
Phone Fax				E-ma	ail	
ADDITIONAL RESULTS RECIPIENTS						
Genetic Counselor or Other Medical Provider Name (Last, First) (Code) Phone/Fax/Email						
PATIENT CLINICAL HISTORY						
Describe (attach clinical notes, family notes)						
Personal History of Cancer Age of Dx Diagnosis Notes (cancer type, etc.) Yes □ No		ICD-10	O Code(s)			
Family History of Cancer Yes No						
Prior Genetic Testing Patient Family Patient Family						
5. TEST ORDERS						
Order Code: 8814 Tissue Culture Baylor Genetics (AG: 7030) Grow and Send	d Ambry Billir	ng ID: AGAC				
REQUIRED: Select a Primary Test Order Select an Optional Supplemental Test (Per payer policy, all tests in this section will be processed and billed separately; tests may be performed as a reflex.)				will be processed		
For Patients Meeting BRCA1/2 Testing Criteria	☐ CancerNext®	® (8824)	☐ CancerNext	-Expanded	® (8875)	
□ BRCA1/2 test	☐ BRCAplus® (8836) Add on: ☐ L		imited Evidence Pancreatitis			
For Patients Meeting Colorectal Cancer Syndrome Testing Criteria (Lynch)	□ BRCANext® (CustomNext	t-Cancer®	(9511)	
Lynch Syndrome test: ☐ MLH1, MSH2, MSH6, PMS2, EPCAM	Add on: ☐ Limited Evidence Notes: ☐ ColoNext® (8821) ☐ Specific Site Analysis (5555): Proband		report is required.			
For Patients Meeting Colorectal Cancer Syndrome Testing Criteria (polyposis)	Add on: Limited Evidence Gene Variant (c./p.):					
Polyposis test: APC/MUTYH			Other:			
Other:		nental Test Options (• • • • • • • • • • • • • • • • • • • •		BANG BANG	1. 16 5111
□ None of the above (patient does not meet any genetic testing criteria)	□ +RNAinsight® (Not available with BRCAplus or STAT orders; PAXgene® tube required for RNA)					
Will the course of treatment change depending upon the results of the test? STAT TEST: Date results needed (if known):						
Was genetic counseling completed? ☐ Yes ☐ No ☐ Unknown Date Genetic Counseling was Performed: Patient Signature (Lagree to terms below): Date:						
Medical Professional Signature (Lagree to terms below):		Date:				
				Date.		
TERMS AND CONDITIONS Patient Acknowledgement: I acknowledge that the information provided by me is true and corre	ect. For direct insur	rance billing: I authori:	ze my insurance b	enefits to	be paid directly to	Ambry Genetics

Patient Acknowledgement: I acknowledge that the information provided by me is true and correct. For direct insurance billing: I authorize my insurance benefits to be paid directly to Ambry Genetic Corporation (Ambry), authorize <u>Ambry</u> to release medical information concerning my testing to my insurer, to be my designated representative for purposes of appealing any denial of benefits as needed and to request additional medical records for this purpose. I understand that I am responsible for sending Ambry money received from my health insurance company.

For NY residents: By checking this box, I agree that Ambry Genetics will retain my sample for 6 months after the testing above has been completed. By not checking this box, I understand that under New York State law, Ambry Genetics must discard my sample after the longer of (a) testing completion and (b) 60 days after the Date of Collection above.

Medical Professional: Confirmation of Informed Consent, Pre-test Genetic Counseling, and Medical Necessity for Genetic Testing

The undersigned person (or representative thereof) ensures he/she is a licensed medical professional authorized to order genetic testing and confirms that the patient has given appropriate consent. I confirm that testing is medically necessary and that test results may impact medical management for the patient. I agree to allow Ambry Genetics to facilitate the provision of pre-test genetic counseling services by a third-party service, as required by the patient's insurance provider. Furthermore, all information on this TRF is true to the best of my knowledge. My signature applies to the attached letter of medical necessity.





Patient Name:	DOB:
---------------	------

Test Requisition for Tissue Culturing (Oncology)

INSTRUCTIONS FOR SUBMITTING SAMPLE TO BAYLOR GENETICS:

KIT REQUEST

- 1. 7-10 days prior to patient's procedure, please place an order for a Baylor Genetics' CVS Transport Media Kit through their website at baylorgenetics.com/supplies.
- 2. On step 3 select "custom options". On step 4 enter TC 8814 at the top and enter the desired qty of 15ml Conical Tube(s) CVS Transport Media.
- 3. For any questions, please contact Baylor Genetics' Client Services at 1-800-411-4363 or email help@baylorgenetics.com.
- 4. Upon receipt of the online kit request, Baylor Genetics will ship a CVS Transport Media Kit to the requested address, which should arrive within 3-5 business days. For urgent kit requests, expedited shipping options are available.

PREPARING SAMPLE

Upon receiving the kit, place tube with media in the refrigerator until ready for use.

Specimen preparation: Collect 5 cubic millimeters of skin from a central location (e.g. buttock or upper thigh) rather than from a distal location (e.g. foot) to enhance cell viability. Place sample in a separate sterile container with RPMI media (included in the Baylor Genetics' CVS Transport Media Kit). In the absence of RPMI media, place sample along with a small amount of sterile saline in a sterile container with a cap that can be tightened to prevent leakage. Never place samples in formalin or other fixative.

Storage/transport temperature: Ship at room temperature in an insulated container by overnight courier. Do NOT heat or freeze.

Stability: Sample must arrive at culture lab within 48 hrs. of collection.

For questions related to tissue culturing, please contact Baylor Genetics' Client Services at 1-800-411-4363 or email help@baylorgenetics.com.

SHIPPING

- 1. Include completed Test Requisition Form with the CVS Transport Media Kit and provide FedEx tracking number.
- 2. Fax (949-900-5501) or email (CulturedSamples@ambrygen.com) completed Test Requisition Form to Ambry Genetics.
- 3. Ship sample to Baylor Genetics at 2450 Holcombe Blvd, Grand Blvd. Receiving Dock, Houston, TX 77021-2024.

Please note that fibroblast cultures typically take 2-3 weeks to complete.

If multiple skin biopsy specimens are collected, only one biopsy specimen will be cultured and sent to Ambry. If you require an exception to the standard specimen processing, please notify Baylor upon sample submission (additional charges may apply). Remaining cultures at Baylor Genetics will be discarded 14 days after sending initial 2 T25s to Ambry, unless additional cultures are requested prior to discard.

For questions related to acceptable specimens, test status, or results, please contact Ambry Genetics at 949-900-5500.



Patient Name		DOB:
--------------	--	------

Supplemental Information

Hereditary Cancer Multi-Gene Tests

TEST NAME	TEST CODE	GENES	
Pan-cancer			
CancerNext® (39 genes)	8824	APC, ATM, AXIN2, BAP1, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDKN2A, CHEK2, EPCAM, FH, FLCN, GREM1, HOXB13, MBD4, MET, MLH1, MSH2, MSH3, MSH6, MUTYH, NF1, NTHL1, PALB2, PMS2, POLD1, POLE, PTEN, RAD51C, RAD51D, SMAD4, STK11, TP53, TSC1, TSC2, VHL	
CancerNext- <i>Expanded®</i> (76 genes or up to 90 genes w/ add-ons)	8875	AIP, ALK, APC, ATM, AXIN2, BAP1, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDC73, CDH1, CDK4, CDKN1B, CDKN2A, CEBPA, CHEK2, CTNNA1, DDX41, DICER1, EGFR, EPCAM, ETV6, FH, FLCN, GATA2, GREM1, HOXB13, KIT, LZTR1, MAX, MBD4, MEN1, MET, MITF, MLH1, MSH2, MSH3, MSH6, MUTYH, NF1, NF2, NTHL1, PALB2, PDGFRA, PHOX2B, PMS2, POLD1, POLE, POT1, PRKAR1A, PTCH1, PTEN, RAD51C, RAD51D, RB1, RET, RUNX1, SDHA, SDHAF2, SDHB, SDHC, SDHD, SMAD4, SMARCA4, SMARCB1, SMARCE1, STK11, SUFU, TMEM127, TP53, TSC1, TSC2, VHL, WT1	
		Optional Add-on 1 - Limited Evidence Genes (9 genes): ATRIP, EGLN1, KIF1B, MLH3, PALLD, RAD51B, RNF43, RPS20, TERT	
		Optional Add-on 2 - Pancreatitis Genes (5 genes): CFTR, CPA1, CTRC, PRSS1, SPINK1	
STAT Breast Management			
BRCAPlus® (13 genes)	8836	ATM, BARD1, BRCA1, BRCA2, CDH1, CHEK2, NF1, PALB2, PTEN, RAD51C, RAD51D, STK11, TP53	
Breast & gynecologic			
BRCANext® (19 genes or up to 26	8857	ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM, MLH1, MSH2, MSH6, NF1, PALB2, PMS2, PTEN, RAD51C, RAD51D, STK11, TP53	
genes w/ add-on)		Optional Add-on - Limited Evidence Genes (7 genes): ATRIP, CDC73, FH, NTHL1, POLD1, POLE, RAD51B	
Colorectal & polyposis			
ColoNovt® (20 gapes or up to 26	8821	APC, AXIN2, BMPR1A, CDH1, EPCAM, GREM1, MBD4, MLH1, MSH2, MSH3, MSH6, MUTYH, NTHL1, PMS2, POLD1, POLE, PTEN, SMAD4, STK11, TP53	
		Optional Add-on - Limited Evidence Genes (6 genes): ATM, CHEK2, CTNNA1, MLH3, RNF43, RPS20	
Customizable			
		To order all genes on Ambry's oncology menu, please order CancerNext-Expanded.	
CustomNext-Cancer® (up to 90 genes) Required: complete CustomNext- Cancer supplemental form. ambrygen.com/forms	9511	AIP, ALK, APC, ATM, ATRIP, AXIN2, BAP1, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDC73, CDH1, CDK4, CDKN1B, CDKN2A, CEBPA, CFTR, CHEK2, CPA1, CTNNA1, CTRC, DICER1, DDX41, EGFR, ELGN1, EPCAM, ETV6, FH, FLCN, GATA2, GREM1, HOXB13, KIF1B, KIT, LZTR1, MAX, MBD4, MEN1, MET, MITF, MLH1, MLH3, MSH2, MSH3, MSH6, MUTYH, NF1, NF2, NTHL1, PALB2, PALLD, PDGFRA, PHOX2B, PMS2, POLD1, POLE, POT1, PRKAR1A, PRSS1, PTCH1, PTEN, RAD51B, RAD51C, RAD51D, RB1, RET, RNF43, RPS20, RUNX1, SDHA, SDHAF2, SDHB, SDHC, SDHD, SMAD4, SMARCA4, SMARCB1, SMARCE1, SPINK1, STK11, SUFU, TERT, TMEM127, TP53, TSC1, TSC2, VHL, WT1	
		For Medicare Patients: At a minimum, the following core genes must be included in the panel to ensure Medicare coverage: APC, ATM, BRCA1, BRCA2, CHEK2, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, PTEN, TP53.	
Syndrome specific			
Adenomatous polyposis	8726	APC, MUTYH	
BRCA1/2-associated hereditary breast and ovarian cancer (HBOC)	8838	BRCA1, BRCA2	
ı			